- Home
- LOBO vs APRE Comparison
LOBO vs APRE Comparison
Compare LOBO & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOBO
- APRE
- Stock Information
- Founded
- LOBO 2014
- APRE 2006
- Country
- LOBO China
- APRE United States
- Employees
- LOBO N/A
- APRE N/A
- Industry
- LOBO
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LOBO
- APRE Health Care
- Exchange
- LOBO NYSE
- APRE Nasdaq
- Market Cap
- LOBO 13.6M
- APRE 8.2M
- IPO Year
- LOBO 2024
- APRE 2019
- Fundamental
- Price
- LOBO $0.66
- APRE $1.59
- Analyst Decision
- LOBO
- APRE Strong Buy
- Analyst Count
- LOBO 0
- APRE 2
- Target Price
- LOBO N/A
- APRE $15.50
- AVG Volume (30 Days)
- LOBO 105.3K
- APRE 30.3K
- Earning Date
- LOBO 05-06-2025
- APRE 05-13-2025
- Dividend Yield
- LOBO N/A
- APRE N/A
- EPS Growth
- LOBO N/A
- APRE N/A
- EPS
- LOBO 0.00
- APRE N/A
- Revenue
- LOBO $19,469,766.00
- APRE $1,502,581.00
- Revenue This Year
- LOBO $72.16
- APRE N/A
- Revenue Next Year
- LOBO $41.04
- APRE N/A
- P/E Ratio
- LOBO $612.06
- APRE N/A
- Revenue Growth
- LOBO N/A
- APRE 157.63
- 52 Week Low
- LOBO $0.46
- APRE $1.41
- 52 Week High
- LOBO $3.52
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- LOBO N/A
- APRE 35.54
- Support Level
- LOBO N/A
- APRE $1.41
- Resistance Level
- LOBO N/A
- APRE $1.59
- Average True Range (ATR)
- LOBO 0.00
- APRE 0.11
- MACD
- LOBO 0.00
- APRE 0.04
- Stochastic Oscillator
- LOBO 0.00
- APRE 45.88
About LOBO LOBO EV TECHNOLOGIES LTD
Lobo EV Technologies Ltd is an electric vehicle manufacturer and seller company. It designs, develops, manufactures, and sells e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons, also provides automobile information and entertainment software development and design services to customers. The company operates in two operating segments: Electric vehicles and accessories sales which generates key revenue, and software royalties and development and design services. It generates all of its revenue within the People's Republic of China.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.